In patients with BRAF V600E-mutated melanoma, the individual EZH2 gain status should be tested first, and cotreatment with BRAF and EZH2 inhibitors can be applied to patients containing EZH2 gain and BRAF V600E mutation simultaneously to enhance the anticancer effects. Here, EZH2 is linked to melanoma.